Polio Sabin.

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MalariaTuberculosisHepatitis B

479 competitors in Malaria

#DrugCompanyPhaseTrials

1

Polio Sabin.

GSK

Phase 3

32

Biltricide

Bayer

Preclinical

13

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

16

IV LBH589

Novartis

Preclinical

17

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

18

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

19

RTS,S/AS01E

GSK

Preclinical

410

Piperaquine

UUniversity of Oxford

Preclinical

3Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00344318·806 enrolled

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Completed·GSK·Phase 2·NCT01262872·1,320 enrolled

A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

Completed·GSK·Phase 2·NCT00263666·100 enrolled

Malaria3 trials

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

Completed·GSK·Phase 3·NCT02207816·3,084 enrolled

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Completed·GSK·Phase 3·NCT00866619·15,459 enrolled

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

Completed·GSK·Phase 2·NCT00436007·511 enrolled

Immunization1 trial

Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A

Completed·GSK·Phase 3·NCT01175083·300 enrolled

Hepatitis B1 trial

Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Completed·GSK·Phase 3·NCT01345240·705 enrolled

Tuberculosis1 trial

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Completed·GSK·Phase 2·NCT01098474·301 enrolled

1 more indication

Children1 trial

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Completed·GSK·Phase 3·NCT00547248·756 enrolled

Details

Drug Info

Related News